NASDAQ:AMED

Amedisys Stock Forecast, Price & News

$166.18
-3.49 (-2.06 %)
(As of 09/16/2021 02:52 PM ET)
Add
Compare
Today's Range
$166.11
$170.83
50-Day Range
$169.64
$270.32
52-Week Range
$166.60
$325.12
Volume4,683 shs
Average Volume241,372 shs
Market Capitalization$5.42 billion
P/E Ratio22.31
Dividend YieldN/A
Beta0.51
30 days | 90 days | 365 days | Advanced Chart
Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.


Amedisys logo

About Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.54 out of 5 stars

Medical Sector

82nd out of 1,352 stocks

Home Health Care Services Industry

2nd out of 10 stocks

Analyst Opinion: 4.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys
or view top-rated stocks.

What stocks does MarketBeat like better than Amedisys?

Wall Street analysts have given Amedisys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amedisys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Amedisys
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) issued its quarterly earnings data on Wednesday, August, 4th. The health services provider reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.02. The health services provider earned $564.17 million during the quarter, compared to the consensus estimate of $565.48 million. Amedisys had a net margin of 11.25% and a trailing twelve-month return on equity of 28.55%. The firm's quarterly revenue was up 16.3% on a year-over-year basis. During the same period last year, the business posted $1.34 EPS.
View Amedisys' earnings history
.

How has Amedisys' stock been impacted by Coronavirus?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMED shares have decreased by 2.5% and is now trading at $166.26.
View which stocks have been most impacted by COVID-19
.

How will Amedisys' stock buyback program work?

Amedisys announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 4th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of $6.370-$6.490 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.960. The company issued revenue guidance of $2.23 million-$2.25 million, compared to the consensus revenue estimate of $2.32 billion.

What price target have analysts set for AMED?

10 Wall Street analysts have issued 1-year target prices for Amedisys' stock. Their forecasts range from $195.00 to $350.00. On average, they expect Amedisys' stock price to reach $269.55 in the next year. This suggests a possible upside of 62.1% from the stock's current price.
View analysts' price targets for Amedisys
or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and The Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.07%), Vanguard Group Inc. (9.62%), Price T Rowe Associates Inc. MD (4.55%), JPMorgan Chase & Co. (3.88%), State Street Corp (2.53%) and Invesco Ltd. (2.53%). Company insiders that own Amedisys stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys
.

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Wells Fargo & Company MN, BlackRock Inc., Invesco Ltd., First Trust Advisors LP, Price T Rowe Associates Inc. MD, Bank of America Corp DE, and PEAK6 Investments LLC. Company insiders that have sold Amedisys company stock in the last year include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, and Scott G Ginn.
View insider buying and selling activity for Amedisys
or view top insider-selling stocks.

Which institutional investors are buying Amedisys stock?

AMED stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Amundi, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Credit Suisse AG, Ensign Peak Advisors Inc, and Allianz Asset Management GmbH. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $166.26.

How much money does Amedisys make?

Amedisys has a market capitalization of $5.43 billion and generates $2.07 billion in revenue each year. The health services provider earns $183.61 million in net income (profit) each year or $6.11 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

Where are Amedisys' headquarters?

Amedisys is headquartered at 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at (225) 292-2031 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.